Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Immune Microenvironment and Clinicopathological Characteristics of Thoracic NUT Carcinoma.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Enterococcus faecalis NBRC 100481 Protects the Intestinal Barrier via α-catenin/HMP-1 in Caenorhabditis elegans.

Probiotics and antimicrobial proteins·2026
Same author

The moderating role of anti-inflammatory diet on the relationship between chronic obstructive pulmonary disease and frailty in older adults: a nationwide cross-sectional and longitudinal study.

BMC geriatrics·2026
Same author

A cold-induced GDF15-secreting adipocyte subpopulation regulates energy homeostasis through endocrine signaling.

Cell reports·2026
Same author

Monodisperse Octahedral PbSe Nanocrystals Encased in Eight (111) Facets and Their Orthorhombic Superlattice.

Journal of the American Chemical Society·2026
Same author

Documentation-derived nursing process indicators and in-hospital outcomes in patients with acute myocardial infarction undergoing PCI: A cohort study.

Medicine·2026

Related Experiment Video

Updated: Jul 6, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K

Targeting HDACs for diffuse large B-cell lymphoma therapy.

Chunyan Wu1, Qiao Song2, Sophie Gao3

  • 1Department of Hematology, The Affiliated Hospital of Qingdao University, No.16 Jiangsu Road, Qingdao, 266003, Shandong, China.

Scientific Reports
|January 3, 2024
PubMed
Summary
This summary is machine-generated.

Histone deacetylases (HDACs) are elevated in diffuse large B-cell lymphoma (DLBCL). Targeting HDACs with Chidamide shows cytotoxic effects, suggesting a potential therapeutic strategy for DLBCL patients.

More Related Videos

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Related Experiment Videos

Last Updated: Jul 6, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Histone deacetylases (HDACs) play a role in cancer development.
  • The specific involvement of HDACs in diffuse large B-cell lymphoma (DLBCL) requires further elucidation.
  • Understanding HDACs' function in DLBCL is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate HDAC expression, mutation status, and clinical significance in DLBCL.
  • To evaluate the therapeutic potential of Chidamide, an HDAC inhibitor, in DLBCL.
  • To provide evidence for targeting HDACs in DLBCL treatment.

Main Methods:

  • Bioinformatic analysis of The Cancer Genome Atlas transcriptome data for HDACs in DLBCL.
  • In vitro studies using DLBCL cell lines to assess Chidamide's effects on proliferation and apoptosis.
  • RNA sequencing and Western blot analysis to explore Chidamide's molecular mechanisms.

Main Results:

  • Significantly higher expression of several HDACs (HDAC1-4, 6-9) was observed in DLBCL lymph node samples compared to controls.
  • Increased mutation rates of HDACs were found in DLBCL tissues.
  • Chidamide demonstrated dose-dependent cytotoxicity against DLBCL cells, impacting key signaling pathways like PI3K/AKT and mTOR.

Conclusions:

  • HDAC gene alterations, including overexpression and mutations, are associated with DLBCL.
  • Chidamide exhibits therapeutic potential by inducing cytotoxicity and affecting critical cellular pathways in DLBCL.
  • Targeting HDACs with inhibitors like Chidamide represents a promising therapeutic avenue for DLBCL patients.